2022
Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer
Mokhtech M, Miccio JA, Johung K, Cecchini M, Stein S, Narang AK, Herman JM, Kunstman J, Haddock MG, Anker CJ, Jabbour S, Hallemeier CL, Jethwa KR. Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer. American Journal Of Clinical Oncology 2022, 45: 450-457. PMID: 36318696, DOI: 10.1097/coc.0000000000000947.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaMultiagent chemotherapyPathologic complete responseStereotactic body radiotherapyOverall survivalComplete responseNonmetastatic pancreatic ductal adenocarcinomaNeoadjuvant multiagent chemotherapyMedian overall survivalNational Cancer DatabaseMargin-negative resectionTreatment of choiceDose/fractionSimilar ratesRegional lymphatic diseaseGy/5 fxNeoadjuvant radiotherapyCox analysisSurgical candidacyProspective evaluationPathologic outcomesBody radiotherapyPancreas cancerCancer DatabaseDuctal adenocarcinoma
2020
Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts).
Stein S, Snider J, McCusker M, Miksad R, Alexander B, Castellanos E, Backenroth D, Schrock A, Madison R, Carson K, Ali S. Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts). Journal Of Clinical Oncology 2020, 38: 310-310. DOI: 10.1200/jco.2020.38.4_suppl.310.Peer-Reviewed Original ResearchComprehensive genomic profilingAdjusted hazard ratioGE cancersOverall survivalERBB2 copy numberERBB2 amplificationClinical outcomesUnadjusted Kaplan-Meier analysisCox proportional hazards modelMedian overall survivalKaplan-Meier analysisEsophageal cancer patientsProportional hazards modelLonger OSHazard ratioMedian ageCancer patientsHER2 expressionHER2 statusTherapy benefitHazards modelHER2Median TTDClinical databaseDiscordant tests
2019
Impact of direct-acting antivirals and 12-week sustained viral response on clinical outcomes in patients with hepatitis C and hepatocellular carcinoma.
Kamp W, Sellers C, Stein S, Lim J, Kim H. Impact of direct-acting antivirals and 12-week sustained viral response on clinical outcomes in patients with hepatitis C and hepatocellular carcinoma. Journal Of Clinical Oncology 2019, 37: 397-397. DOI: 10.1200/jco.2019.37.4_suppl.397.Peer-Reviewed Original ResearchHepatitis C viral infectionDAA therapyOverall survivalHepatocellular carcinomaMultivariable analysisViral responseHCC patientsTumor locationTreatment allocationHigher OSMultivariable Cox proportional hazards modelsUrban tertiary care hospitalCox proportional hazards modelHCV-negative patientsChild-Pugh scoreMedian overall survivalSustained viral responseTertiary care hospitalC viral infectionKaplan-Meier curvesProportional hazards modelDAA patientsHCV patientsHepatitis CMELD score
2018
The effect of socioeconomic factors on the outcome of hepatocellular carcinoma.
Sellers C, Ludwig J, Uhlig J, Stein S, Taddei T, Kim H. The effect of socioeconomic factors on the outcome of hepatocellular carcinoma. Journal Of Clinical Oncology 2018, 36: 466-466. DOI: 10.1200/jco.2018.36.4_suppl.466.Peer-Reviewed Original ResearchMedian overall survivalCancer-directed treatmentOverall survivalHepatocellular carcinomaPrivate insurancePrimary insuranceInner-city tertiary care hospitalDecreased median overall survivalCox proportional hazard modelingMultivariate Cox proportional analysisCox proportional analysisTertiary care hospitalOS of patientsKaplan-Meier curvesProportional hazard modelingSocioeconomic factorsMedian OSSurvival benefitCare hospitalConsecutive patientsAJCC stageCancer RegistryMean ageTreatment courseSurvival advantageThe effect of socioeconomic factors on the outcome of intrahepatic cholangiocarcinoma.
Sellers C, Ludwig J, Uhlig J, Stein S, Lacy J, Kim H. The effect of socioeconomic factors on the outcome of intrahepatic cholangiocarcinoma. Journal Of Clinical Oncology 2018, 36: 465-465. DOI: 10.1200/jco.2018.36.4_suppl.465.Peer-Reviewed Original ResearchMedian overall survivalOverall survivalIntrahepatic cholangiocarcinomaPrimary insurancePrivate insuranceLocoregional therapyInner-city tertiary care hospitalDecreased median overall survivalCox proportional hazard modelingCancer-directed treatmentOS of patientsTertiary care hospitalKaplan-Meier curvesProportional hazard modelingPrivate insurance patientsSocioeconomic factorsConsecutive patientsCare hospitalCancer RegistryMean ageTreatment coursePreventive careEarly treatmentMedicaid patientsInsurance patients
2017
A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC).
Eads J, Stein S, El-Khoueiry A, Manji G, Abrams T, Khorana A, Miksad R, Mahalingam D, Sirard C, Zhu A, Goyal L. A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC). Journal Of Clinical Oncology 2017, 35: 4075-4075. DOI: 10.1200/jco.2017.35.15_suppl.4075.Peer-Reviewed Original ResearchBiliary tract cancerAdvanced biliary tract cancerTreatment-emergent adverse eventsAdverse eventsPartial responseGrade 3/4 treatment-emergent adverse eventsAST/ALT elevationMonoclonal antibodiesDisease control rateEmergent adverse eventsMedian overall survivalFirst-line therapySerious adverse eventsDuration of responseHumanized monoclonal antibodyVEGF-C expressionInhibits cell invasionPromoter of metastasisDKN-01Median PFSALT elevationPrior regimensStable diseaseMedian durationProgressive diseaseSWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer.
Kim R, McDonough S, El-Khoueiry A, Bekaii-Saab T, Stein S, Sahai V, Keogh G, Kim E, Baron A, Siegel A, Barzi A, Guthrie K, Javle M, Hochster H. SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer. Journal Of Clinical Oncology 2017, 35: 4016-4016. DOI: 10.1200/jco.2017.35.15_suppl.4016.Peer-Reviewed Original ResearchProgression-free survivalGrade 3 toxicityMedian overall survivalOverall survivalArm BResponse rateArm ATreatment-related grade 3 toxicitiesMedian progression-free survivalAdvanced biliary cancerGemcitabine/platinumSecond-line treatmentPhase II trialHigh-grade toxicityStandard treatment optionMEK inhibitor trametinibOverall response rateInterim futility analysisEarly promising resultsLack of responseEligible patientsInfusional 5FUStable diseaseII trialPrimary endpoint
2013
Phase II study of mFOLFOX with bevacizumab (Bev) in metastatic gastroesophageal and gastric (GE) adenocarcinoma (AC).
Li J, Kortmansky J, Fischbach N, Stein S, Yao X, Hochster H, Lacy J. Phase II study of mFOLFOX with bevacizumab (Bev) in metastatic gastroesophageal and gastric (GE) adenocarcinoma (AC). Journal Of Clinical Oncology 2013, 31: 4084-4084. DOI: 10.1200/jco.2013.31.15_suppl.4084.Peer-Reviewed Original ResearchCisplatin-based regimensOverall survivalGE adenocarcinomaResponse rateMetastatic sitesProspective phase II trialECOG PS 0/1Grade 3/4 toxicitiesMedian overall survivalPhase II studyPhase II trialPhase III studyDVT/PELiver 19Median TTPPrior gastrectomyPS 0/1GI perforationHemorrhagic eventsII studyII trialIII studyMedian survivalMedian ageGastric adenocarcinoma